Multi-centre, Open-label Trial to Assess the saFety, Pharmacodynamics, Efficacy and Pharmacokinetics of pegunigaLsidase Alfa in Patients From 2 Years to Less Than 18 Years of Age With Confirmed FabrY Disease
Status: Recruiting
Location: See all (12) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents with Fabry Disease.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 2
Maximum Age: 17
Healthy Volunteers: f
View:
• Participants with the provision of informed consent from their legal guardians
• Boys and girls aged 2 to 7 years (Cohort A), 8 to 12 years (Cohort B), or 13 to \<18 years (Cohort C).
• Confirmed diagnosis of Fabry disease
• Presence of at least one of the following characteristic features of Fabry disease: neuropathic pain, cornea verticillata, and/or clustered angiokeratoma.
• History of Fabry pain: Fabry crises OR chronic pain.
• Clinical condition that, in the investigator's opinion, requires ERT treatment.
Locations
United States
Arizona
Phoenix Children's
RECRUITING
Phoenix
Georgia
Emory Genetics Clinical Trials Center
RECRUITING
Atlanta
Iowa
University of Iowa
RECRUITING
Iowa City
Ohio
Cincinnati Children's Hospital Medical Center
RECRUITING
Cincinnati
Utah
University of Utah
RECRUITING
Salt Lake City
Virginia
Lysosomal and Rare Disorders Research and Treatment Center Inc
RECRUITING
Fairfax
Other Locations
Austria
UK für Kinder- und Jugendheilkunde der PMU Salzburg
RECRUITING
Salzburg
France
Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Pellegrin
RECRUITING
Bordeaux
Hopital Arnaud de Villeneuve
RECRUITING
Montpellier
Norway
Haukeland Universitetssjukehus
RECRUITING
Bergen
Spain
Hospital Clinico Universitario De Santiago De Compostela
RECRUITING
Santiago De Compostela
United Kingdom
Great Ormond Street Hospital for Children NHS Foundation Trust
NOT_YET_RECRUITING
London
Contact Information
Primary
Chiesi Clinical Trial
clinicaltrials_info@chiesi.com
+3905212791
Time Frame
Start Date: 2025-07-29
Estimated Completion Date: 2031-04
Participants
Target number of participants: 22
Treatments
Experimental: Single Arm - Pegunigalsidase alfa (PRX-102)
For Cohort C, PXR-102 administered every two weeks at 1.0 mg/kg is believed to be the minimum effective dose.~For Cohorts A and B, the starting dose will be 1.0 mg/kg every two weeks but it may be adjusted on the outcomes of Stage I, with the support of the Data Safety Monitoring Board.
Related Therapeutic Areas
Sponsors
Collaborators: ICON plc
Leads: Chiesi Farmaceutici S.p.A.